Skip to main content
Charles Loprinzi, MD, Oncology, Rochester, MN

Charles L Loprinzi MD


Professor of Medicine, Mayo Medical School

Join to View Full Profile
  • 200 1st St SwMayo Clinic, Dept Med OncologyRochester, MN 55905

  • Phone+1 507-284-2511

Dr. Loprinzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1982 - 1984
  • Creighton University School of Medicine/Maricopa Medical Center (Phoenix)
    Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 1979 - 1982
  • Oregon Health and Science University School of Medicine
    Oregon Health and Science University School of MedicineClass of 1979

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1985 - 2026
  • AZ State Medical License
    AZ State Medical License 1988 - 2017
  • FL State Medical License
    FL State Medical License 1987 - 2005
  • WI State Medical License
    WI State Medical License 1982 - 1985
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2003-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Fellow (FASCO) American Society of Clinical Oncologists, 2008

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply  
    Charles L Loprinzi, Rudolph M Navari, JAMA Oncology
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting  
    Rudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology

Lectures

  • Scrambler therapy for established chemotherapy-induced neuropathy: A randomized phase II trial. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Mayo Clinic Oncology Review 
    Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 7/20/2013
  • MSCO Fellows Dinner Meeting 
    Minnesota Society of Clinical Oncology (MSCO), Minneapolis, Minnesota - 7/20/2013
  • Join now to see all

Other

Authored Content

  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020

Press Mentions

  • Charles B. Hammond, M.D.,
    Charles B. Hammond, M.D.,September 30th, 2024
  • ASCO Voices 2020
    ASCO Voices 2020August 9th, 2020
  • What Is Peripheral Neuropathy and How Can It Be Prevented or Treated?
    What Is Peripheral Neuropathy and How Can It Be Prevented or Treated?July 14th, 2020
  • Join now to see all

Grant Support

  • Survivorship Research Established Investigator AwardNational Cancer Institute2008–2011
  • Statistical Support UnitNational Cancer Institute2007–2011
  • Nursing And PharmacyNational Cancer Institute2007–2011
  • Community Clinical Oncology ProgramNational Cancer Institute2004–2011
  • SupplementNational Cancer Institute2007–2008
  • Operations UnitNational Cancer Institute2007
  • CapitationNational Cancer Institute2007
  • AuditNational Cancer Institute2007
  • AdministrationNational Cancer Institute2007
  • Ncctg CCOP Research Base - Foreign AccrualNational Cancer Institute2006
  • Community Clinical Oncology Program - Foreign AccrualNational Cancer Institute2005
  • Ncctg Foreign AccrualsNational Cancer Institute2004
  • Foreign Accural - NcctgNational Cancer Institute2003
  • Cancer Chemoprevention--Role Of Infection/ImmunityNational Cancer Institute1999–2003
  • Community Clinical Oncology ProgramNational Cancer Institute1994–2003
  • Inhibition Of Ornithine Decarboxylase By Oral CompoundsNational Cancer Institute1985

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: